GlassScriptPhysician profile
Sarah K Baxt
NPI 1649725458
$2,169.61
in general payments reported to CMS, 2019-2025
24 companies · $555 in 2025
The $555 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $615 · 2022: $267 · 2023: $516 · 2024: $217 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $880.86 | 2021-2025 | Proclaim, Eterna |
| Abbvie INC. | $239.76 | 2021-2025 | |
| Boston Scientific Corporation | $220.15 | 2025 | Intracept, Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $176.00 | 2021-2024 | Belbuca, Xtampza |
| Medtronic, INC. | $75.82 | 2021-2023 | Intellis Adaptivestim |
| Nalu Medical, INC. | $69.66 | 2025 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $67.12 | 2021-2022 | |
| Spr Therapeutics, INC | $53.98 | 2022-2023 | Sprint Pns System |
| Virtus Pharmaceuticals LLC | $48.38 | 2024 | Levorphanol Tartrate |
| Si-Bone, INC. | $39.43 | 2025 | |
| Pfizer INC. | $29.52 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $26.48 | 2021 | |
| Nevro Corp. | $25.94 | 2021-2022 | |
| Grt US Holding, INC. | $25.14 | 2022 | |
| Painteq LLC | $23.91 | 2023 | Painteq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $23.79 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.12 | 2022 | |
| Lilly USA, LLC | $22.91 | 2025 | Zepbound, Mounjaro |
| Averitas Pharma INC. | $19.63 | 2023 | Qutenza |
| Masimo Corporation | $18.25 | 2023 | Patient Safetynet System |
| Scilex Pharmaceuticals INC. | $16.17 | 2021 | |
| Forte Bio-Pharma LLC | $15.28 | 2024 | Prolate, Nalocet |
| Azurity Pharmaceuticals, INC. | $14.42 | 2024 | Horizant |
| Arbor Pharmaceuticals, INC. | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Baxt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.